Women's Cancer Program
The Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute brings together Cedars-Sinai physicians and scientists to focus on how cancer impacts women. This includes both gender-specific cancers (such as breast and ovarian), and other cancers that may affect women differently than men (such as lung cancer).
The Women’s Cancer Program, led by Beth Karlan, MD, represents a comprehensive approach that emphasizes research and cross disciplinary linkages to Cedars-Sinai’s clinical programs.
The Women’s Cancer Program is committed to studying cancer biology to develop new approaches to early detection, prevention and individualized treatments that will improve overall cancer survival for women.
As one of the country’s foremost translational research programs, the Women’s Cancer Program offers a wide variety of research protocols and clinical trials.
The goals of the Women’s Cancer Program include:
- To foster research between scientists and physicians and accelerate the translation of innovative laboratory discoveries directly to women with breast and/or gynecologic cancers.
- To use these insights to identify “druggable” molecular targets and companion diagnostics for early detection, prognostication and therapy.
- To identify modifiable risk factors that can be optimized to reduce the cancer burden in women.
- To work side-by-side with Cedars-Sinai patient care programs to integrate research findings across a wide spectrum of programs devoted to preventing, diagnosing and treating women's cancers.
In the 2012-13 U.S. News & World Report Best Hospitals issue, Cedars-Sinai once again ranked among America's best in Cancer.
